As the use of nanoparticles becomes more prevalent, it is clear that human exposure will inevitably increase. Considering the rapidly ageing European population and the resulting increase in the incidence of neurodegenerative diseases, there is an urgent need to address the risk presented by nanoparticles towards neurodegenerative diseases. It is believed that nanoparticles can pass through the blood-brain barrier. Once in the brain, nanoparticles have two potential major effects. They can induce oxidative activity (production of Reactive Oxygen Species), and can induce anomalous protein aggregation behaviour (fibrillation). There are multiple disease targets for the nanoparticles, including all of the known fibrillation diseases (e.g. Alzheimer’s and Parkinson’s diseases). The factors that determine which nanoparticles enter the brain are not known. Nanoparticle size, shape, rigidity and composition are considered important, and under physiological conditions, the nature of the adsorbed biomolecule corona (proteins, lipids etc.) determines the biological responses. The NeuroNano project will investigate the detailed mechanisms of nanoparticle passage through the blood-brain barrier using primary cell co-cultures and animal studies. Using nanoparticles that are shown to reach the brain, we will determine the mechanisms of ROS production and protein fibrillation, using state-of-the-art approaches such as redox proteomics and isolation/characterisation of the critical pre-fibrillar species. Animal models for Alzheimer’s diseases will confirm the effects of the nanoparticles in vivo. At all stages the exact nature of the nanoparticle biomolecule corona will be determined. The result will be a risk-assessment framework for assessing the safety of nanoparticles towards neurodegenerative diseases, based on the connection of their biological effects to their biomolecule corona, which determines the biological response in vivo and reports on the nanoparticles’ history.